{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:58:53Z","timestamp":1789595933110,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003125","name":"Suomen Kulttuurirahasto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.msard.2022.103755","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T20:23:44Z","timestamp":1647721424000},"page":"103755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-9631","authenticated-orcid":false,"given":"Ilkka","family":"Rauma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Viitala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kuusisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Atula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi O T","family":"Sipil\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervi","family":"Ryytty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja","family":"Soilu-H\u00e4nninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"J\u00e4rvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103755_bib0001","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.103755_bib0002","doi-asserted-by":"crossref","unstructured":"Baker, D., Herrod, S.S., Alvarez-Gonzalez, C., Zalewski, L., Albor, C., Schmierer, K., 2017. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol. - Neuroimmunol. Neuroinflammation 4, e360. doi:10.1212\/NXI.0000000000000360.","DOI":"10.1212\/NXI.0000000000000360"},{"key":"10.1016\/j.msard.2022.103755_bib0003","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","article-title":"Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations","volume":"8","author":"Barry","year":"2019","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2022.103755_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102945","article-title":"A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis","volume":"52","author":"Bose","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103755_bib0005","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"Ceronie","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.103755_bib0006","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103755_bib0007","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103755_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101938","article-title":"Severe fingolimod rebound syndrome after switching to cladribine treatment","volume":"40","author":"Coss-Rovirosa","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103755_bib0009","unstructured":"European Medicines Agency, 2021. MAVENCLAD EU Summary of Product Characteristics [WWW Document]. URL https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf (accessed 9.14.21)."},{"key":"10.1016\/j.msard.2022.103755_bib0010","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103755_bib0011","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing\u2013remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.103755_bib0012","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ane.13145","article-title":"Multiple sclerosis in Finland 2018\u2014Data from the national register","volume":"140","author":"Laakso","year":"2019","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2022.103755_bib0013","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.103755_bib0014","article-title":"Therapy with cladribine is efficient and safe in patients previously treated with natalizumab. Ther","volume":"12","author":"M\u00f6hn","year":"2019","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.103755_bib0015","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-\u03b2 in active relapsing MS","volume":"5","author":"Montalban","year":"2018","journal-title":"Neurol. - Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2022.103755_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101498","article-title":"Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation","volume":"38","author":"Mustonen","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103755_bib0017","article-title":"Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther","volume":"13","author":"Patti","year":"2020","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.103755_bib0018","article-title":"Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres","author":"Pfeuffer","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.103755_bib0019","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/ane.13295","article-title":"Changes in multiple sclerosis epidemiology in Finland over five decades","volume":"142","author":"Pirttisalo","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2022.103755_bib0020","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther","volume":"12","author":"Prosperini","year":"2019","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.103755_bib0021","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1212\/NXI.0000000000000990","article-title":"Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol. - Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2022.103755_bib0022","article-title":"Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Ther","volume":"12","author":"Stuve","year":"2019","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.103755_bib0023","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, N.C.I., 2017. Common Terminology Criteria for Adverse Events v5.0 [WWW Document]. URL https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482200270X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482200270X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:01:33Z","timestamp":1761901293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482200270X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":23,"alternative-id":["S221103482200270X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103755","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103755"}}